![]()
15
| 4 | 2010
Klinisk Biokemi i Norden
Referencer
1. Garnacho-Montero J, Garcia-Garmendia
JL, Barrero-Almodovar A, Jimenez-Jimenez
FJ, Perez-Paredes C, Ortiz-Leyba C. Impact
of adequate empirical antibiotic therapy
on the outcome of patients admitted to the
intensive care unit with sepsis. Crit Care
Med 2003;31:2742-51.
2. Alberti C, Brun-Buisson C, Goodman SV,
Guidici D, Granton J, Moreno R, et al. Influ-
ence of systemic inflammatory response
syndrome and sepsis on outcome of criti-
cally ill infected patients. Am J Respir Crit
Care Med 2003;168:77-84.
3. Alberti C, Brun-Buisson C, Burchardi H,
Martin C, Goodman S, Artigas A, et al.
Epidemiology of sepsis and infection in
ICU patients from an international mul-
ticentre cohort study. Intensive Care Med
2002;28:108-21.
4. Kollef MH, Sherman G, Ward S, Fraser
VJ. Inadequate antimicrobial treatment of
infections: a risk factor for hospital mor-
tality among critically ill patients. Chest
1999;115:462-74.
5. Kumar A, Roberts D, Wood KE, Light B,
Parrillo JE, Sharma S, et al. Duration of
hypotension before initiation of effective
antimicrobial therapy is the critical deter-
minant of survival in human septic shock.
Crit Care Med 2006;34:1589-96.
6. Dellinger RP, Levy MM, Carlet JM, Bion
J, Parker MM, Jaeschke R, et al. Surviving
Sepsis Campaign: international guidelines
for management of severe sepsis and septic
shock: 2008. Crit Care Med 2008;36:296-
327.
7. Castelli GP, Pognani C, Cita M, Stuani A,
Sgarbi L, Paladini R. Procalcitonin, C-reac-
tive protein, white blood cells and SOFA
score in ICU: diagnosis and monitoring of
sepsis. Minerva Anestesiol 2006;72:69-80.
8. Lavrentieva A, Kontakiotis T, Lazaridis
L, Tsotsolis N, Koumis J, Kyriazis G, et
al. Inflammatory markers in patients with
severe burn injury. What is the best indica-
tor of sepsis? Burns 2007;33:189-94.
9. Jensen JU, Heslet L, Jensen TH, Espersen K,
Steffensen P, Tvede M. Procalcitonin incre-
ase in early identification of critically ill
patients at high risk of mortality. Crit Care
Med 2006;34:2596-602.
10. Gaini S, Koldkjaer OG, Moller HJ, Peder-
sen C, Pedersen SS. A comparison of high-
mobility group-box 1 protein, lipopolysac-
charide-binding protein and procalcitonin
in severe community-acquired infections
and bacteraemia: a prospective study. Crit
Care 2007,11(4):R76.
11. Ventetuolo CE, Levy MM. Biomarkers:
diagnosis and risk assessment in sepsis.
Clin Chest Med 2008;29:591-603, vii.
12. Weglohner W, Struck J, Fischer-Schulz C,
Morgenthaler NG, Otto A, Bohuon C, et
al. Isolation and characterization of serum
procalcitonin from patients with sepsis.
Peptides 2001;22:2099-103.
13. Birnbaum RS, Mahoney WC, Burns DM,
O’Neil JA, Miller RE, Roos BA. Identifi-
cation of procalcitonin in a rat medullary
thyroid carcinoma cell line. J Biol Chem
1984;259:2870-4.
14. Assicot M, Gendrel D, Carsin H, Raymond J,
Guilbaud J, Bohuon C. High serum procalci-
tonin concentrations in patients with sepsis
and infection. Lancet 1993;341:515-8.
15. Muller B, White JC, Nylen ES, Snider RH,
Becker KL, Habener JF. Ubiquitous expres-
sion of the calcitonin-i gene in multiple tis-
sues in response to sepsis. J Clin Endocrinol
Metab 2001;86:396-404.
16. Burns DM, Forstrom JM, Friday KE,
Howard GA, Roos BA. Procalcitonin’s
amino-terminal cleavage peptide is a bone-
cell mitogen. Proc Natl Acad Sci U S A
1989; 23:9519-23.
17. Monneret G, Arpin M, Venet F, Maghni K,
Debard AL, Pachot A, et al. Calcitonin gene
related peptide and N-procalcitonin modu-
late CD11b upregulation in lipopolysaccha-
ride activated monocytes and neutrophils.
Intensive Care Med 2003;29:923-8.
(Fortsætter side 16)
